[Other] Design and rationale of a phase 1 dose-escalation study of AMG 193, a methylthioadenosine (MTA)-cooperative PRMT5 inhibitor, in patients with advanced methylthioadenosine phosphorylase (MTAP)-null solid tumors. |
Reward10points
|
post
reply
points
1080
50
Towards an Approach for Analyzing Dynamic Aspects of Bias and Beyond-Accuracy Measures
10
Comparative numerical investigations on aerodynamic performance of plain flaps using CFD for fixed-wing UAVs
50
Intracranial Aneurysms Managed by Parent Artery Reconstruction Using Tubridge Flow Diverter study: 1-year outcomes
20
Effect of Denture Liners Surface Modification WithEquisetum GiganteumandPunica GranatumonCandida AlbicansBiofilm Inhibition
20
Imaging findings in Giant Cell Arteritis: Don’t Turn A Blind Eye To The Obvious!
